Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -206.81M | -208.93M | -208.02M | -214.90M | -185.98M |
| Total Depreciation and Amortization | -- | -- | -- | 0.00 | 0.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 41.10M | 47.65M | 55.14M | 80.85M | 65.06M |
| Change in Net Operating Assets | 11.54M | -8.58M | -4.53M | -17.20M | -35.50M |
| Cash from Operations | -154.18M | -169.86M | -157.41M | -151.25M | -156.42M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 7.00M | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.87M | -248.38M | -353.29M | -218.01M | -358.38M |
| Cash from Investing | -48.87M | -248.38M | -353.29M | -218.01M | -358.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Common Stock | 240.07M | 239.84M | 243.89M | 102.80M | 89.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 0.00 | 0.00 | 169.21M | 253.76M | 253.76M |
| Repurchase of Preferred Stock | -220.00K | -355.00K | -355.00K | -355.00K | -12.77M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -617.00K | -617.00K | -1.84M | -7.29M | -7.22M |
| Cash from Financing | 239.24M | 238.87M | 410.91M | 348.91M | 323.60M |
| Foreign Exchange rate Adjustments | 1.00K | 1.00K | -3.00K | 30.00K | -3.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.19M | -179.38M | -99.79M | -20.32M | -191.21M |